Regulated production and anti-HIV type 1 activities of cytidine deaminases APOBEC3B, 3F, and 3G

AIDS Research and Human Retroviruses

Volumn 21, Issue 7, 2005, Pages 611-619

  Rose, Kristine M ^a   Marin, Mariana ^a   Kozak, Susan L ^a   Kabat, David ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; COMPLEMENTARY DNA; CYTIDINE DEAMINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHORBOL 13 ACETATE 12 MYRISTATE; RNA; VIF PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; VIRION; VIRUS CELL INTERACTION;

ANTIVIRAL AGENTS; BASE SEQUENCE; BLOTTING, NORTHERN; CYTIDINE DEAMINASE; CYTOSINE DEAMINASE; DNA PRIMERS; GENE PRODUCTS, VIF; HELA CELLS; HUMANS; MOLECULAR SEQUENCE DATA; NUCLEOSIDE DEAMINASES; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 23444450544     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.611     Document Type: Article

References (72)

1. Rose KM, Marin M, Kozak SL, and Kabat D: The viral infectivity factor (Vif) of HIV-1 unveiled. Trends Mol Med 2004;10:291-297.
2. Liu B, Yu X, Luo K, Yu Y, and Yu XF: Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol 2004;78:2072-2081.
3. Marin M, Rose KM, Kozak SL, and Kabat D: HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 2003;9:1398-1403.
4. Mariani R, et al.: Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003;114:21-31.
5. Mehle A, et al.: Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. J Biol Chem 2003;279:7792-7798.
6. Sheehy AM, Gaddis NC, Choi JD, and Malim MH: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002;418:646-650.
7. Sheehy AM, Gaddis NC, and Malim MH: The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 2003;9:1404-1407.
8. Stopak K, de Noronha C, Yonemoto W, and Greene WC: HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 2003;12:591-601.
9. Yu X, et al.: Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003;302:1056-1060.
10. Gabuzda DH, et al.: Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol 1992;66:6489-6495.
11. Fan L and Peden K: Cell-free transmission of Vif mutants of HIV-1. Virology 1992;190:19-29.
12. Sakai H, et al.: Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J Virol 1993;67:1663-1666.
13. von Schwedler U, Song J, Aiken C, and Trono D: Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol 1993;67:4945-4955.
14. Shah RR, et al.: Sequence requirements for the editing of apolipoprotein B mRNA. J Biol Chem 1991;266:16301-16304.
15. Anant S, et al.: ARCD-1, an apobec-1-related cytidine deaminase, exerts a dominant negative effect on C to U RNA editing. Am J Physiol Cell Physiol 2001;281:C1904-1916.
16. Jarmuz A, et al.: An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 2002;79:285-296.
17. Douaisi M, et al.: HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles. Biochem Biophys Res Commun 2004;321:566-573.
18. Alce TM and Popik W: APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein. J Biol Chem 2004;279:34083-34086.
19. Cen S, et al.: The interaction between HIV-1 Gag and APOBEC3G. J Biol Chem 2004;279:33177-33184.
20. Zhang H, et al.: The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003;424:94-98.
21. Yu Q, et al.: Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat Struct Mol Biol 2004;11:435-442.
22. Shindo K, et al.: The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. J Biol Chem 2003;278:44412-44416.
23. Mangeat B, et al.: Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003;424:99-103.
24. Liddament MT, Brown WL, Schumacher AJ, and Harris RS: APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 In vivo. Curr Biol 2004;14:1385-1391.
25. Bishop KN, et al.: Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Curr Biol 2004;14:1392-1396.
26. Wiegand HL, Doehle BP, Bogerd HP, and Cullen BR: A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. Embo J 2004;23:2451-2458.
27. Zheng YH, et al.: Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. J Virol 2004;78:6073-6076.
28. Yu Q, et al.: APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication. J Biol Chem 2004;279:53379-53386.
29. Garrett ED, Tiley LS, and Cullen BR: Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products. J Virol 1991;65:1653-1657.
30. Zhang J and Webb DM: Rapid evolution of primate antiviral enzyme APOBEC3G. Hum Mol Genet 2004;13:1785-1791.
31. Sawyer SL, Emerman M, and Malik HS: Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G. PLoS Biol 2004 2:E275.
32. Mangeat B, Turelli P, Liao S, and Trono D: A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action. J Biol Chem 2004;279:14481-14483.
33. Bogerd HP, Doehle BP, Wiegand HL, and Cullen BR: A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor. Proc Natl Acad Sci USA 2004;101:3770-3774.
34. Xu H, et al.: A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion. Proc Natl Acad Sci USA 2004;101:4296-4301.
35. Schrofelbauer B, Chen D, and Landau NR: A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif). Proc Natl Acad Sci USA 2004;101:3927-3932.
36. Conticello SG, Harris RS, and Neuberger MS: The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Curr Biol 2003;13:2009-2013.
37. Harris RS, Petersen-Mahrt SK, and Neuberger MS: RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell 2002;10:1247-1253.
38. Harris RS, et al.: DNA deamination mediates innate immunity to retroviral infection. Cell 2003;113:803-809.
39. Kobayashi M, et al.: APOBEC3G targets specific virus species. J Virol 2004;78:8238-8244.
40. Yamamoto Y, et al.: Functional analysis of vif genes derived from various primate immunodeficiency viruses. Virus Genes 1997;14:195-200.
41. Simon JH, Southerling TE, Peterson JC, Meyer BE, and Malim MH: Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J Virol 1995;69:4166-4172.
42. Reddy TR, et al.: Comparative analyses of human immunodeficiency virus type 1 (HIV-1) and HIV-2 Vif mutants. J Virol 1995;69:3549-3553.
43. Ribeiro AC, et al.: Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G. J Virol 2005;79:823-833.
44. Platt EJ, Wehrly K, Kuhmann SE, Chesebro B, and Kabat D: Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998;72:2855-2864.
45. Tailor CS, Nouri A, Lee CG, Kozak C, and Kabat D: Cloning and characterization of a cell surface receptor for xenotropic and polytropic murine leukemia viruses. Proc Natl Acad Sci USA 1999;96:927-932.
46. Rose KM, Marin M, Kozak SL and Kabat D: Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus. J Biol Chem 2004;279:41744-41749.
47. Madani N and Kabat D: Cellular and viral specificities of human immunodeficiency virus type 1 vif protein. J Virol 2000;74:5982-5987.
48. Wedekind JE, Dance GS, Sowden MP, and Smith HC: Messenger RNA editing in mammals: New members of the APOBEC family seeking roles in the family business. Trends Genet 2003;19:207-216.
49. Nguyen KL, et al.: Codon optimization of the HIV-1 vpu and vif genes stabilizes their mRNA and allows for highly efficient Rev-independent expression. Virology 2004;319:163-175.
50. Gaddis NC, Chertova E, Sheehy AM, Henderson LE, and Malim MH: Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions. J Virol 2003;77:5810-5820.
51. Gaddis NC, et al.: Further investigation of simian immunodeficiency virus Vif function in human cells. J Virol 2004;78:12041-12046.
52. Fujita M, et al.: Analysis of the cell-dependent replication potentials of human immunodeficiency virus type 1 vif mutants. Microbes Infect 2001;3:1093-1099.
53. Fouchier RA, Simon JH, Jaffe AB, and Malim MH: Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol 1996;70:8263-8269.
54. Hevey M and Donehower LA: Complementation of human immunodeficiency virus type 1 vif mutants in some CD4+ T-cell lines. Virus Res 1994;33:269-280.
55. Michaels FH, Hattori N, Gallo RC, and Franchini G: The human immunodeficiency virus type 1 (HIV-1) vif protein is located in the cytoplasm of infected cells and its effect on viral replication is equivalent in HIV-2. AIDS Res Hum Retroviruses 1993;9:1025-1030.
56. Rasmussen HH and Celis JE: Evidence for an altered protein kinase C (PKC) signaling pathway in psoriasis. J Invest Dermatol 1993;101:560-566.
57. Cascalho M: Advantages and disadvantages of cytidine deamination. J Immunol 2004;172:6513-6518.
58. Anant S and Davidson NO: Identification and regulation of protein components of the apolipoprotein B mRNA editing enzyme. A complex event. Trends Cardiovasc Med 2002;12:311-317.
59. Smith HC, Bottaro A, Sowden MP, and Wedekind JE: Activation induced deaminase: The importance of being specific. Trends Genet 2004;20:224-227.
60. Mehta A, Kinter MT, Sherman NE, and Driscoll DM: Molecular cloning of apobec-1 complementation factor, a novel RNA-binding protein involved in the editing of apolipoprotein B mRNA. Mol Cell Biol 2000;20:1846-1854.
61. Yoshikawa K, et al.: AID enzyme-induced hypermutation in an actively transcribed gene in fibroblasts. Science 2002;296:2033-2036.
62. Okazaki IM, et al.: Constitutive expression of AID leads to tumorigenesis. J Exp Med 2003;197:1173-1181.
63. Sowden M, Hamm JK, and Smith HC: Overexpression of APOBEC-1 results in mooring sequence-dependent promiscuous RNA editing. J Biol Chem 1996;271:3011-3017.
64. Yang Y, Sowden MP, and Smith HC: Induction of cytidine to uridine editing on cytoplasmic apolipoprotein B mRNA by overexpressing APOBEC-1. J Biol Chem 2000;275:22663-22669.
65. Hersberger M, et al.: Regulatable liver expression of the rabbit apolipoprotein B mRNA-editing enzyme catalytic polypeptide 1 (APOBEC-1) in mice lacking endogenous APOBEC-1 leads to aberrant hyperediting. Biochem J 2003;369:255-262.
66. Chang F, et al.: Signal transduction mediated by the Ras/Raf/MEK/ ERK pathway from cytokine receptors to transcription factors: Potential targeting for therapeutic intervention. Leukemia 2003;17:1263-1293.
67. Meloche S: Cell cycle reentry of mammalian fibroblasts is accompanied by the sustained activation of p44mapk and p42mapk isoforms in the G1 phase and their inactivation at the G1/S transition. J Cell Physiol 1995;163:577-588.
68. Pages G, et al.: Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci USA 1993;90:8319-8323.
69. Chen R, Le Rouzic E, Kearney JA, Mansky LM, and Benichou S: Vpr-mediated incorporation of UNG2 into HIV-1 particles is required to modulate the virus mutation rate and for replication in macrophages. J Biol Chem 2004;279:28419-28425.
70. Priet S, Navarro JM, Gros N, Querat G, and Sire J: Functional role of HIV-1 virion-associated uracil DNA glycosylase 2 in the correction of G:U mispairs to G:C pairs. J Biol Chem 2003;278:4566-4571.
71. Soudeyns H, Geleziunas R, Shyamala G, Hiscott J, and Wainberg MA: Identification of a novel glucocorticoid response element within the genome of the human immunodeficiency virus type 1. Virology 1993;194:758-768.
72. Ciuffi A, et al.: Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection. J Virol 2004;78:10747-10754.